Farnum Rhonda's Form 4 filing
Theravance Biopharma, Inc. (TBPH) · filed Jul 16, 2025
- Accession no.
- 0001415889-25-019869
- Filed
- Jul 16, 2025
- Trade date
- Jul 14, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $113.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Farnum RhondaCIK 0001898490 | Officer (SVP, COMM & MEDICAL AFFAIRS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 14, 2025 | Ordinary Shares | SSaleDisposed | −682 | $11.39 | −$7,767.98 | 336,236 | Direct | |
| Jul 14, 2025 | Ordinary Shares | SSaleDisposed | −5,318 | $11.39 | −$60,572.02 | 330,918 | Direct | |
| Jul 14, 2025 | Ordinary Shares | SSaleDisposed | −4,000 | $11.39 | −$45,560 | 326,918 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.